Hanmi R&D becomes stronger through cooperation with partners.

As a long-acting glucagon-like peptide (GLP-1), gastric inhibitory peptide (GIP) and glucagon triple agonist, HM15275 achieves more favorable pharmacodynamics profile in addition to once-weekly dosing. Based on Hanmi’s expertise on incretin science, HM15275 is rationally designed and developed to provide specialized therapeutic outcomes for severe obesity and associated metabolic disorders such as dyslipidemia and T2DM.

GLP-1 receptor agonist could reduce body weight by increasing satiety (appetite ↓) and could improve insulin secretion/sensitivity to improve glycemic control. GIP provides and enhances the pharmacological benefits of GLP-1 receptor agonist. Furthermore, when combined with GLP-1, GIP could relieve common gastrointestinal-related adverse effects in GLP-1 receptor agonist such as nausea, vomiting and diarrhea. In addition to play an essential role in blood glucose homeostasis, glucagon is also involved in regulation of energy expenditure and lipid metabolism along with satiety control. Therefore, suitable harmonization of these three components could maximize the therapeutic potential for obesity, type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD).

Nonclinical research suggests the best-in-class potential of HM15275 for treating obesity and cardiovascular renal metabolism (CVRM) diseases. Currently, an Investigational New Drug (IND) application has been submitted for a phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) study.